Product logins

Find logins to all Clarivate products below.

home   •  Research Reports  •  Disease Landscape and Forecast Insights

Acute Heart Failure – How Are Novel Therapies Differentiated from Current Treatment Options in This Highly Genericized Market? | Decision Base | US/EU5 | 2015

Login to access report north_east
Contact sales account_box

How Are Novel Therapies Differentiated from Current Treatment Options in This Highly Genericized Market?

Acute heart failure (AHF) is one of the leading causes of hospitalization in the developed world, representing a significant healthcare burden. Treatment of AHF relies on different lines of therapy to relieve symptoms and to encourage sufficient hemodynamic stabilization. Long-term patient prognosis remains bleak: both mortality and hospital readmission rates are very high. The high attrition rate of drugs in development for AHF has resulted in a very genericized market in which no new therapies have launched since 2002. However, the AHF therapies in development boast promising new mechanisms of action and have the potential to fill the gaps in efficacy and safety left by current agents.

Contact sales account_box
Login to access report north_east

Related Market Assessment Reports

Report
Postpartum Depression – Current Treatment – Treatment Algorithms: Claims Data Analysis – Postpartum Depression (US)
Postpartum depression (PPD) refers to depression experienced by women after childbirth. The PPD drug market consists of very limited treatment options specifically approved for PPD, so drugs used…
north_east
Report
Type 1 Diabetes – Current Treatment – Treatment Algorithms: Claims Data Analysis – Type 1 Diabetes (US)
Intensive insulin regimens have proven effective in delaying the progression of complications associated with untreated or poorly treated type 1 diabetes (T1D). Thus, insulin remains the…
north_east
Report
Biosimilars – Current Treatment – Ophthalmology
The ophthalmology market is relatively new in the field of biosimilars: Samsung Bioepis / Biogen’s ranibizumab biosimilar, Byooviz, was the first MAb biosimilar to launch in the U.S. market in…
north_east
Report
Venous Thromboembolism – Current Treatment – Treatment Algorithms: Claims Data Analysis – Venous Thromboembolism (US)
Venous thromboembolism (VTE) is the obstruction of a vein caused by a thrombus. It consists of deep vein thrombosis (DVT) and pulmonary embolism (PE), depending on the vein affected. Current…
north_east
Report
Thyroid Eye Disease – Executive Insights – Thyroid Eye Disease | Executive Insights (US)
north_east

Follow us

Contact us

Sales enquiries north_east
Customer service north_east
Support north_east